MedDataX Logo

Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients

NCT ID: NCT00408759

Last Updated: 2006-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

xerostomia develops in all patients with head and neck cancer following radiotherapy. it consists one of the main side effects which affects quality of life. currently, there is no standard of care for treating this condition. parasympathomimetic drugs may help but carry significant side effects.

hypnosis may affect autonomic function such as salivation, in healthy people.in this study we will explore the efficacy of hypnosis in improving salivation, in the patient population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

10 head and neck cancer patients with xerostomia following radiotherapy will be assessed for severity of xerostomia using questionnares and quantitative salivation tests. patients responsive to citric acid will receive a hypnotic session with specific suggestion for salivation. saliva volume will be assessed pre and post hypnosis. patients will receive a CD with recorded hypnotic session to use freely at home. xerostomia will be assessed using a questionnare one week following hypnosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Xerostomia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

xerostomia hypnosis dry mouth radiotherapy head and neck cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hypnosis

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* radiotherapy for head and neck cancer
* xerostomia

Exclusion Criteria

* psychiatric illness (present or past)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bnai Zion Medical Center

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elad Schiff

Role: PRINCIPAL_INVESTIGATOR

Bnai Zion MC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

bnai zion MC

Haifa, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

elad schiff

Role: CONTACT

Phone: 972482654767

Email: [email protected]

gorge mogilner

Role: CONTACT

Phone: 97248359359

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

elad schiff

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

eschiff

Identifier Type: -

Identifier Source: org_study_id